In This Section
Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema
To guide referring and imaging physicians to use Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema, the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Society for Vascular Medicine (SVM), Australia and New Zealand Society of Nuclear Medicine (ANZSNM), American College of Radiology (ACR), Society of Surgical Oncology (SSO), European Association of Nuclear Medicine (EANM), American Head and Neck Society (AHNS), American Society of Clinical Oncology (ASCO), American Society of Breast Surgeons (ASBrS), American College of Nuclear Medicine (ACNM), and American College of Surgeons (ACS) worked collaboratively to develop criteria for the Appropriate Use Document.
SNMMI assembled an autonomous workgroup to represent a multidisciplinary panel of health care providers with substantive knowledge in the use of nuclear medicine procedures for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema imaging to review the scientific literature and develop consensus recommendations for the clinical use of this technology. The Oregon Health Science University's (OHSU) Evidence-based Practice Center (EPC) conducted a systematic review of existing evidence based on the scope and parameters the Imaging Workgroup put together, The systematic review was used to make their recommendations for clinical use.
Click here to view AUC for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema
To view the development process, please click the following link: SNMMI AUC Development Process.